PE20100449A1 - Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas - Google Patents

Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas

Info

Publication number
PE20100449A1
PE20100449A1 PE2010000020A PE2010000020A PE20100449A1 PE 20100449 A1 PE20100449 A1 PE 20100449A1 PE 2010000020 A PE2010000020 A PE 2010000020A PE 2010000020 A PE2010000020 A PE 2010000020A PE 20100449 A1 PE20100449 A1 PE 20100449A1
Authority
PE
Peru
Prior art keywords
dysplasia
metaplasia
stains
detection
proliferative diseases
Prior art date
Application number
PE2010000020A
Other languages
English (en)
Inventor
Kai Licha
Michael Schirner
Martin Pessel
Malte Bahner
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100449(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20100449A1 publication Critical patent/PE20100449A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE CIANINA SF64, DE FORMULA (I) EN UNA CANTIDAD QUE PERMITE DETECTAR UNA ENFERMEDAD PROLIFERATIVA, CON UNA LESION PROLIFERATIVA DE 7mm DE DIAMETRO. DICHA CANTIDAD SE ADMINISTRA ENTRE 0.001 Y 0.5 mg/Kg DE PESO CORPORAL POR CADA APLICACION DE DIAGNOSTICO. REFIERE TAMBIEN QUE LA LESION PROLIFERATIVA ES: A) UNA PRECANCEROSIS TALES COMO QUERATOSIS ACTINICA, CUERNO CUTANEO, QUERATOSIS ACTINICA, ENTRE OTROS; B) UNA METAPLASIA TALES COMO UNA METAPLASIA MIELOIDE ANGIOGENICA, METAPLASIA APOCRINA, METAPLASIA ATIPICA, ENTRE OTROS; C) UNA DISPLASIA, TALES COMO DISPLASIA ECTODERMICA ANHIDROTICA, DISPLASIA ANTEROFACIAL, DISPLASIA TORACICA ASFIXIANTE; D) ENFERMEDAD OFTALMICA TALES COMO TRACOMA, RETINOPATIA DEL PREMATURO, GLAUCOMA NEOVASCULAR, ENTRE OTROS
PE2010000020A 2005-01-07 2006-01-05 Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas PE20100449A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05000276A EP1679082A1 (en) 2005-01-07 2005-01-07 Use of cyanine dyes for the diagnosis of proliferative diseases

Publications (1)

Publication Number Publication Date
PE20100449A1 true PE20100449A1 (es) 2010-07-25

Family

ID=34933224

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2006000039A PE20060872A1 (es) 2005-01-07 2006-01-05 Colorantes de cianina en el diagnostico de enfermedades proliferativas
PE2010000020A PE20100449A1 (es) 2005-01-07 2006-01-05 Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2006000039A PE20060872A1 (es) 2005-01-07 2006-01-05 Colorantes de cianina en el diagnostico de enfermedades proliferativas

Country Status (23)

Country Link
EP (2) EP1679082A1 (es)
JP (1) JP5578765B2 (es)
KR (1) KR20070092270A (es)
CN (1) CN101128218A (es)
AR (1) AR052190A1 (es)
AU (1) AU2006204496A1 (es)
BR (1) BRPI0606411A2 (es)
CA (1) CA2594390C (es)
CR (1) CR9232A (es)
DO (1) DOP2006000005A (es)
GT (1) GT200600001A (es)
IL (1) IL182499A0 (es)
MX (1) MX2007008300A (es)
NO (1) NO20074036L (es)
NZ (1) NZ554917A (es)
PA (1) PA8659101A1 (es)
PE (2) PE20060872A1 (es)
RU (1) RU2007129919A (es)
TW (1) TW200635612A (es)
UA (1) UA89976C2 (es)
UY (1) UY29323A1 (es)
WO (1) WO2006072580A1 (es)
ZA (1) ZA200706533B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE374367T1 (de) * 2004-07-22 2007-10-15 Bayer Schering Pharma Ag Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases
EP1743658A1 (en) * 2005-07-14 2007-01-17 Schering Aktiengesellschaft Optical imaging of rheumatoid arthritis
WO2008119493A1 (en) * 2007-03-30 2008-10-09 F. Hoffmann-La Roche Ag Composition of labeled and non-labeled monoclonal antibodies
US20110262354A1 (en) 2007-07-13 2011-10-27 Emory University Cyanine-containing compounds for cancer imaging and treatment
GB0803477D0 (en) 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
CN102099059B (zh) * 2008-06-13 2015-09-23 西塞医疗中心 用于癌症靶向治疗的小分子配体-药物轭合物
GB0814960D0 (en) * 2008-08-15 2008-09-24 Ge Healthcare As Method for detecting dysplasia
JP2012532846A (ja) 2009-07-09 2012-12-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト インビボ腫瘍脈管構造画像処理
CA2768330A1 (en) 2009-07-28 2011-02-03 F. Hoffmann-La Roche Ag Non-invasive in vivo optical imaging method
AU2010286592B2 (en) 2009-08-28 2015-08-13 Visen Medical, Inc. Systems and methods for tomographic imaging in diffuse media using a hybrid inversion technique
JP2011046663A (ja) 2009-08-28 2011-03-10 Fujifilm Corp 近赤外蛍光造影剤
JP2011046662A (ja) 2009-08-28 2011-03-10 Fujifilm Corp 近赤外蛍光造影剤
US8401619B2 (en) 2009-09-22 2013-03-19 Visen Medical, Inc. Systems and methods for virtual index-matching of diffusive media
WO2011138462A1 (en) 2010-05-07 2011-11-10 F. Hoffmann-La Roche Ag Diagnostic method for the detection of cells ex vivo
WO2012119999A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag Means and methods for in vivo testing of therapeutic antibodies
EP2683413A1 (en) 2011-03-07 2014-01-15 F.Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
KR101373108B1 (ko) 2012-01-20 2014-03-27 이화여자대학교 산학협력단 폴리메틴 체인에 메조-반응작용기를 갖는 신규한 시아닌 유도체 및 이의 제조방법
CN102608051B (zh) * 2012-02-21 2015-04-08 中国科学院化学研究所 用于诊断白血病的试剂盒
CN102703569B (zh) * 2012-05-24 2014-04-09 中国科学院化学研究所 菁染料的新用途
CN102706787B (zh) * 2012-05-24 2015-04-08 中国科学院化学研究所 菁染料的新用途
CN104853669B (zh) 2012-10-15 2017-07-21 文森医学公司 具有荧光及生物发光源的交叉形态加权特征的漫射介质成像的系统、方法及设备
US20150182518A1 (en) * 2012-10-26 2015-07-02 Canon Kabushiki Kaisha Cancer cell inhibitory drug and cancer stem-cell detection probe
WO2014092958A1 (en) * 2012-12-10 2014-06-19 Molecular Targeting Technologies, Inc. Compositions and methods of diagnosing ocular diseases
JP6681334B2 (ja) 2013-12-31 2020-04-15 メモリアル スローン ケタリング キャンサー センター リアルタイムの蛍光源のマルチチャネル撮像のためのシステム、方法、および装置
RU2565645C1 (ru) * 2014-09-05 2015-10-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ рентгендиагностики глубины инвазии рецидива рака вульвы в мягкие ткани
EP3233134B1 (en) 2014-12-15 2020-03-25 Memorial Sloan-Kettering Cancer Center Cyclic peptides with enhanced nerve-binding selectivity, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging
CA3007657A1 (en) 2015-12-15 2017-06-22 Memorial Sloan Kettering Cancer Center Imaging systems and methods for tissue differentiation, e.g., for intraoperative visualization
US11660354B2 (en) 2016-11-30 2023-05-30 Memorial Sloan Kettering Cancer Center Inhibitor-functionalized ultrasmall nanoparticles and methods thereof
CN111970960A (zh) 2018-03-30 2020-11-20 珀金埃尔默健康科学有限公司 使用短波红外(swir)投影层析成像对解剖器官和内含物进行3d重建的系统和方法
EP4015004A1 (en) 2020-12-18 2022-06-22 Phi Pharma SA Proteoglycan specific branched peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
DE19917713A1 (de) * 1999-04-09 2000-10-19 Diagnostikforschung Inst Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik
DE19947559A1 (de) * 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
MXPA05007668A (es) * 2003-01-24 2005-09-30 Schering Ag Colorantes hidrofilicos de cianina, reactivos a tiol y conjugados de los mismos con biomoleculas para diagnostico por fluorescencia.
ATE374367T1 (de) * 2004-07-22 2007-10-15 Bayer Schering Pharma Ag Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases

Also Published As

Publication number Publication date
NZ554917A (en) 2010-01-29
CR9232A (es) 2007-11-23
JP5578765B2 (ja) 2014-08-27
AU2006204496A1 (en) 2006-07-13
CA2594390A1 (en) 2006-07-13
DOP2006000005A (es) 2006-07-15
TW200635612A (en) 2006-10-16
KR20070092270A (ko) 2007-09-12
UY29323A1 (es) 2006-10-02
NO20074036L (no) 2007-08-03
CA2594390C (en) 2013-10-22
EP1679082A1 (en) 2006-07-12
EP1833513B1 (en) 2013-03-06
ZA200706533B (en) 2009-07-29
JP2008526802A (ja) 2008-07-24
MX2007008300A (es) 2007-09-07
AR052190A1 (es) 2007-03-07
RU2007129919A (ru) 2009-02-20
EP1833513A1 (en) 2007-09-19
WO2006072580A1 (en) 2006-07-13
BRPI0606411A2 (pt) 2009-06-23
PA8659101A1 (es) 2006-09-08
IL182499A0 (en) 2007-09-20
CN101128218A (zh) 2008-02-20
PE20060872A1 (es) 2006-10-01
UA89976C2 (ru) 2010-03-25
GT200600001A (es) 2006-08-22

Similar Documents

Publication Publication Date Title
PE20100449A1 (es) Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas
ES2526648T3 (es) Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno
US10010526B2 (en) Heterocyclic flavone derivatives, compositions, and methods related thereto
CU20100200A7 (es) Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias
AR076949A1 (es) Derivados de 1h-imidazo-(4,5-c)-quinolinona
CR9748A (es) Derivados de xantina como agonistas selectivos de hm74a
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
BRPI0608853B8 (pt) composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes
PE20040121A1 (es) Formulaciones farmaceuticas de liberacion controlada del 5,8,14-triazatetraciclo [10.3.1.02,11.04.9]-hexadeca-2-(11),3,5,7,9-pentaeno
JP2007534657A5 (es)
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
CR20120040A (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, procedimientos para su preparación y su uso para el tratamiento de enfermedades
DOP2010000263A (es) Derivados de imidazo-[1,2-b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met
GT200500309A (es) Derivados de sulfonilbencilimidazol
EP2822386A1 (en) Folate receptor alpha binding ligands
SG152254A1 (en) Contrast agents for myocardial perfusion imaging
AR074778A1 (es) Composicion farmaceutica, con anticuerpo monoclonal humano anti - igf-ir.
EA200300507A1 (ru) Радиофармацевтические агенты для диагностики болезни альцгеймера
WO2009070652A1 (en) Method of treating cancer
CL2007002899A1 (es) Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros.
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
ECSP10010247A (es) Derivados heterocíclicos
PE20020173A1 (es) Uso de uno o mas antagonistas de aldosterona para el tratamiento o profilaxis de enfermedades mediadas por aldosterona
AR047438A1 (es) Sal amina de derivado de carboestirilo
PE20190608A1 (es) Composicion farmaceutica que comprende antagonista de receptor mineralocorticoide y su uso

Legal Events

Date Code Title Description
FD Application declared void or lapsed